An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Pharmaceutical giant Novo Nordisk says an oral version of semaglutide — the active ingredient in blockbuster drugs Ozempic ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Two major clinical trials evaluating the potential of the weight-loss drug semaglutide to treat Alzheimer’s disease have ...

Despite encouraging biomarker shifts, oral semaglutide failed to slow cognitive decline in early Alzheimer’s, leading to an early end of the trial extension.

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

Novo Nordisk shares plunge after its oral semaglutide Alzheimer’s trials fail, raising fresh doubts over its push into a ...

Based on the efficacy results, Novo Nordisk has made the decision to discontinue the 1-year extension periods for these trials.

experts comment on news from Novo Nordisk that semaglutide does not reduce Alzheimer’s Disease progression Prof Tara Spires-Jones, Director of the Centre for Discovery Brain Sciences at the University ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.